Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
    • UDDA Revision Series
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
    • UDDA Revision Series
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

March 13, 2012; 78 (11) Writeclick: Editor's Choice

A Randomized Trial of High-Dose Vitamin D2 in Relapsing-remitting Multiple Sclerosis

Helmut H. Leitner, L. Grimaldi, F. Barkhof, M. Beelke, J. Burton, T. Holmoy, R. Hupperts, J. Killestein, P. Rieckmann, M. Schluep, J. Smolders, ; on behalf of the SOLAR study group
First published March 12, 2012, DOI: https://doi.org/10.1212/01.wnl.0000413180.13413.ce
Helmut H. Leitner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L. Grimaldi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F. Barkhof
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Beelke
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Burton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. Holmoy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Hupperts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Killestein
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. Rieckmann
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Schluep
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Smolders
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
A Randomized Trial of High-Dose Vitamin D2 in Relapsing-remitting Multiple Sclerosis
Helmut H. Leitner, L. Grimaldi, F. Barkhof, M. Beelke, J. Burton, T. Holmoy, R. Hupperts, J. Killestein, P. Rieckmann, M. Schluep, J. Smolders
Neurology Mar 2012, 78 (11) 840-841; DOI: 10.1212/01.wnl.0000413180.13413.ce

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
1170

Share

  • Article
  • Info & Disclosures
Loading

Stein et al.1 compared high- vs low-dose vitamin D2 treatment in MS without benefit in the high-dose treatment group. Sunlight exposure and reduced vitamin D3 levels independently contribute to MS risk. The effect of sunlight exposure is supported by decreased signs of actinic skin damage found in MS patients compared to controls.2 It is difficult to determine which of these 2 environmental factors is of primary importance as higher levels of sunlight exposure will enhance vitamin D levels.

The incidence of vitamin D–related rickets disease decreased in the United States and Europe during the last century following the discovery that vitamin D possessed antirachitic properties, whereas the incidence of MS seemed to increase in the same population. In the United States, most of the patients with rickets are African American, whereas the majority of patients with MS are of European ancestry.3 It seems improbable that the same environmental factor should be centrally involved in the etiology of both diseases, which differ clinically and occur in different populations living in the same geographic area.

These findings together with those of Stein et al. do not provide a reason for vitamin D supplementation in MS aside from correcting a proven vitamin D deficiency. Other factors associated with increased sunlight exposure may more effectively prevent MS.

The conclusion of Stein et al.1 that high-dose ineffective vs low-dose vitamin D2 supplementation in relapsing-remitting MS (RRMS) is not supported by data enabling level 1 evidence.

Randomization to interferon-β, glatiramer acetate, or no treatment results in very small treatment groups. Such MRI-based randomized placebo-controlled trials would need at least 85 patients per arm to reach statistical significance, assuming 50% treatment difference4 and, since vitamin D effects may appear after 12–24 weeks, an MRI follow-up period of at least 9—not 6—months.

In figure 2, only 4/11 subjects in the higher dose group exhibited 25(OH)D levels within the 130–175 nmol/L target range.1 Since dosages must have been adjusted continuously throughout the trial, likely fluctuations in serum 25(OH)D prevent firm conclusions.5

During the study, MKTVIF75HV (vitamin D2) was replaced by vitamin D3. As vitamin D2 and D3 are not equivalent,5 these results cannot be extended to all “vitamin D” subtypes.

To address these issues, an appropriately powered, randomized, double-blind, placebo-controlled, phase II study (SOLAR) of high-dose vitamin D3 (vigantol oil, 14,000 IU/d) add-on to interferon β–1a, 44 μg subcutaneously 3 times weekly (Rebif), for 96 weeks in 348 RRMS patients, is currently under way.6

References

  1. 1.↵
    1. Stein MS,
    2. Liu Y,
    3. Gray OM,
    4. et al
    . A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology 2011; 77: 1611– 1618.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Lucas RM,
    2. Ponsonby AL,
    3. Dear K,
    4. et al
    . Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology 2011; 76: 540– 548.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Nield LS,
    2. Mahajan P,
    3. Joshi A,
    4. Kamat D
    . Rickets: not a disease of the past. Am Fam Physician 2006; 74: 619– 626.
    OpenUrlPubMed
  4. 4.↵
    1. Sormani M,
    2. Miller D,
    3. Comi G,
    4. et al
    . Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculation based on large data sets. J Neurol Neurosurg Psychiatry 2001; 70: 494– 499.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Hiremath GS,
    2. Cettomai D,
    3. Baynes M,
    4. et al
    . Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis. Mult Scler 2009; 15: 735– 740.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Smolders J,
    2. Hupperts R,
    3. Barkhof F,
    4. et al
    . Efficacy of vitamin D(3) as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a phase II, multicenter, double -blind, randomized, placebo-controlled trial. J Neurol Sci 2011; 311: 44– 49.
    OpenUrlCrossRefPubMed
  • Copyright © 2012 by AAN Enterprises, Inc.
View Abstract

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • References
  • Info & Disclosures
Advertisement

Association of Mediterranean-DASH Intervention for Neurodegenerative Delay and Mediterranean Diets With Alzheimer Disease Pathology

Dr. Babak Hooshmand and Dr. David Smith

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 101 (13)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise